- Home
- GTEC vs NNVC Comparison
GTEC vs NNVC Comparison
Compare GTEC & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- NNVC
- Stock Information
- Founded
- GTEC 2006
- NNVC 2005
- Country
- GTEC United States
- NNVC United States
- Employees
- GTEC N/A
- NNVC N/A
- Industry
- GTEC Industrial Machinery/Components
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- GTEC Industrials
- NNVC Health Care
- Exchange
- GTEC Nasdaq
- NNVC Nasdaq
- Market Cap
- GTEC 21.2M
- NNVC 23.1M
- IPO Year
- GTEC N/A
- NNVC N/A
- Fundamental
- Price
- GTEC $1.21
- NNVC $1.53
- Analyst Decision
- GTEC
- NNVC
- Analyst Count
- GTEC 0
- NNVC 0
- Target Price
- GTEC N/A
- NNVC N/A
- AVG Volume (30 Days)
- GTEC 159.8K
- NNVC 152.4K
- Earning Date
- GTEC 11-13-2025
- NNVC 11-13-2025
- Dividend Yield
- GTEC N/A
- NNVC N/A
- EPS Growth
- GTEC N/A
- NNVC N/A
- EPS
- GTEC 0.53
- NNVC N/A
- Revenue
- GTEC $81,601,160.00
- NNVC N/A
- Revenue This Year
- GTEC $3.28
- NNVC N/A
- Revenue Next Year
- GTEC N/A
- NNVC $133.33
- P/E Ratio
- GTEC $2.32
- NNVC N/A
- Revenue Growth
- GTEC N/A
- NNVC N/A
- 52 Week Low
- GTEC $1.14
- NNVC $0.94
- 52 Week High
- GTEC $2.92
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- GTEC 39.65
- NNVC 60.59
- Support Level
- GTEC $1.21
- NNVC $1.30
- Resistance Level
- GTEC $1.31
- NNVC $1.46
- Average True Range (ATR)
- GTEC 0.07
- NNVC 0.07
- MACD
- GTEC -0.01
- NNVC 0.01
- Stochastic Oscillator
- GTEC 13.64
- NNVC 68.18
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.